More MS news articles for May 2002

Atlantic's CT-3 Shows Promising Multiple Sclerosis Results in Animal Models

Tuesday May 7, 8:41 am Eastern Time
Press Release
SOURCE: Atlantic Technology Ventures, Inc.

NEW YORK--(BW HealthWire)--May 7, 2002--Atlantic Technology Ventures, Inc.'s (OTCBB: ATLC - news) proprietary lead compound CT-3 demonstrated anti-spastic activity in an animal model of multiple sclerosis at a dose level achievable in humans.

The study, conducted by Professor Dr. David Baker of the Institute of Neurology, University College London, UK, provides further evidence of CT-3's potent anti-spastic and analgesic effects. CT-3 is also identified as Ajulemic Acid, a non-psychoactive synthetic derivative of a metabolite of tertrahydrocannabinol (THC).

"The results that CT-3 has exhibited in this experimental model of multiple sclerosis are very exciting and worthy of further exploration," said Michael Ferrari, Vice President of Business Development of Atlantic. "Tremor and spasticity symptoms in MS are very difficult to control. This study provides a rationale for the therapeutic potential of CT-3 in the control of the symptoms of MS. Consequently, plans for Phase II clinical trials are underway for this indication."

Spasticity is a common, painful sign that develops during multiple sclerosis (MS) and following spinal cord injury. Current therapy is often associated with dose-limiting adverse side-effects. In the study, CT-3 induced a significant decrease in spasticity, demonstrated a rapid inhibition of limb stiffness and the effect was relatively long-lived. The data suggested that the dose of CT-3 tested exhibited near maximal inhibition of spasticity. The results of the study validated spasticity as a potential indication for CT-3 use. Compared to other cannabinoids such as Tetrahydorcannabinol (THC) and Cannabidiol (CBD) tested in the same animal model (Nature, March 2000), CT-3 appeared to be 100 times more potent in relieving the symptoms of tremor and spasticity.

The Institute of Neurology is part of the University College London (UCL) Campus. The Institute of Neurology is an internationally recognized center for multiple sclerosis research and has conducted many clinical trials and has a wide patient database. The ethos of the Institute is to link basic and clinical scientists for the benefit of neurological research. The Institute of Neurology is part of the Medical Research Council funded study to examine medical cannibis in symptom control. Should compounds prove therapeutically promising, the Institute is in an ideal position to move the basic science studies forward into Phase II trials in patients. The Institute is currently the only place worldwide with an academic research interest in both experimental and clinical control of spasticity.

About Atlantic Technology Ventures, Inc.

Atlantic is engaged in the development of biomedical and pharmaceutical products and related technologies. Atlantic's strategy is to identify nascent medical products and technologies that have the potential to address unmet market needs, rapidly develop these through a definitive proof-of-principle, then partner, license or sell them to realize significant revenue. Atlantic currently has ownership interest in Avantix (formerly known as "Catarex"), a surgical device for cataract removal, and CT-3, a synthetic cannabinoid derivative for treating pain and inflammation.

Safe Harbor Statement

Cautionary statement under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995: This press release contains certain forward-looking statements that relate to future scientific, business and financial performance. These statements are only predictions and are subject to a number of risks and uncertainties that may cause the actual events or results to differ from those discussed or implied in these statements. These risks and uncertainties include competition from other manufacturers of related technologies, the unavailability of any necessary intellectual property rights possessed by third parties, and certain of those risks described in Atlantic's most recent report on Form 10-KSB with the Securities and Exchange Commission.


     The Investor Relations Group, New York
     Shayne Payne / Dian Griesel, Ph.D.

Copyright © 2002 Yahoo! Inc